Syndax Pharmaceuticals Inc
SNDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.81B
Close$
$-0.81
104.1% downside
Current Fair Value
104.1% downsideOvervalued by 104.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.81 Billion |
|---|---|
| Enterprise Value | $2.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.29 |
| Beta | 0.37 |
| Outstanding Shares | 88,991,317 |
Return
| Return on Equity | -1462.12% |
|---|---|
| Return on Assets | -31.37% |
| Return on Invested Capital | -23.78% |
Valuation & Multiples
| P/E Ratio | -8.1 |
|---|---|
| PEG | 25.87 |
| Price to Sales | 9.9 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.18 |
| Enterprise Value to EBIT | -14.35 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 39.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.45
Average shareholder expectationRevenue Estimate
$79.36 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$85.50 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9111▲ 24.71% |
|---|---|
| Total Calls | 66,400▼ 85.06% |
| Total Puts | 60,500▼ 79.50% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 22.29%▼ 92.42% |
|---|---|
| Total Invested | $422.19M▼ 81.80% |
| Investors Holding | 72▼ 188.00% |
ESG Score
No data
About Syndax Pharmaceuticals Inc
CEO: Arlene Morris